Patents by Inventor Barry John Langham

Barry John Langham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8637491
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: January 28, 2014
    Assignee: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • Patent number: 8604051
    Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 10, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20130296338
    Abstract: A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: September 2, 2011
    Publication date: November 7, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Quincey
  • Patent number: 8487101
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: July 16, 2013
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham
  • Patent number: 8394822
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: March 12, 2013
    Assignee: UCB Pharma, S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 8350037
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: January 8, 2013
    Assignee: UCB Pharma, S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20120329774
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 27, 2012
    Applicant: UCB Pharma S.A.
    Inventors: Clive Martin Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 8283359
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: October 9, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Martin Clive Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20120095005
    Abstract: A series of substituted pyrazolo[1,5-?][1,3,5]triazine and pyrazolo[1,5-?j-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).
    Type: Application
    Filed: May 19, 2010
    Publication date: April 19, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Barry John Langham, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Publication number: 20110172191
    Abstract: A series of thieno[2,3-b]pyridine derivatives, attached at the 2-position to a substituted anilino moiety, which are substituted in the 3-position by a carbonyl group linked to a pyrrolidin-1-yl ring which in turn forms part of a heteroatom-containing fused bicyclic ring system, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: December 17, 2010
    Publication date: July 14, 2011
    Applicant: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Thorne
  • Publication number: 20110021558
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: July 20, 2010
    Publication date: January 27, 2011
    Applicant: UCB Pharma S.A.
    Inventors: Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham
  • Patent number: 7763729
    Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F(1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N? atom or a —C(Rb)? group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH? group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: July 27, 2010
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Publication number: 20100179124
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 15, 2010
    Applicant: UCB Pharma S.A.
    Inventors: James Andrew Johnson, Daniel Christopher Brookings, Martin Clive Hutchings, Barry John Langham, Judi Charlotte Neuss
  • Publication number: 20100179185
    Abstract: The present invention concerns novel 3-aminothienopyridinone derivatives of the formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: November 23, 2007
    Publication date: July 15, 2010
    Applicant: UCB PHARMA, S.A.
    Inventors: Jeremy Martin Davis, Daniel Christopher Brookings, Barry John Langham, Martin Clive Hutchings
  • Publication number: 20090264411
    Abstract: A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: February 13, 2009
    Publication date: October 22, 2009
    Applicant: UCB Pharma S.A.
    Inventors: Victoria Elizabeth Laing, Daniel Christopher Brookings, Rachel Jane Carbery, Jose Miguel Gascon Simorte, Martin Clive Hutchings, Barry John Langham, Martin Alexander Lowe
  • Patent number: 7592455
    Abstract: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: September 22, 2009
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Publication number: 20090149437
    Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
    Type: Application
    Filed: July 30, 2008
    Publication date: June 11, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Clive Martin Hutchings, Sarah Catherine Archibald, Daniel Christopher Brookings, Jeremy Martin Davis, James Andrew Johnson, Barry John Langham, Judi Charlotte Neuss
  • Patent number: 7521460
    Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: April 21, 2009
    Assignee: UCB Pharma S.A.
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Publication number: 20090042877
    Abstract: Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a —N? atom or a —C(Rb)? group, or the dashed line is absent and A is a —N(Rb)—, or —C(Rb)(Rc)— group; X is an —O—, —S— or substituted nitrogen atom or a —S(O)—, —S(O2)— or —NH-group; Y is a nitrogen or substituted carbon atom or a —CH? group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.
    Type: Application
    Filed: August 7, 2008
    Publication date: February 12, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Daniel Christopher Brookings, Jeremy Martin Davis, Barry John Langham
  • Patent number: 7456286
    Abstract: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: November 25, 2008
    Assignee: UCB Pharma, S.A.
    Inventors: Daniel Christopher Brookings, Rachel Jane Cubbon, Jeremy Martin Davis, Barry John Langham